The scientific rationale for long-acting biologics in dermatology.

The evolution of biologic therapies in dermatology increasingly emphasizes extending drug half-life to optimize pharmacokinetics and therapeutic durability. Mechanisms such as FcRn-mediated recycling, Fc engineering, albumin binding, PEGylation, and amino acid polymer technologies enhance systemic persistence and stabilize drug exposure. These advances enable sustained inhibition of key inflammatory pathways, including IL-23/T-helper 17 and IL-4/IL-13, reducing disease relapse and improving long-term outcomes. Extended half-life biologics also improve adherence, reduce immunogenicity, and lessen treatment burden through infrequent dosing. Collectively, these innovations represent a shift toward precision pharmacology, matching drug kinetics with disease biology to enhance efficacy, patient satisfaction, and health care efficiency in chronic dermatologic conditions.